Abstract
Multiple sclerosis patients treated with highly active treatments (natalizumab, ocrelizumab) have an increased risk of infections. Natalizumab discontinuation can produce a rebound effect, consisting of severe disease reactivation. We aim to study the management and safety of MS patients on natalizumab during the Covid-19 pandemic.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
